| Value | ₹977.8 Cr |
|---|---|
| Execution period | Up to financial year 2028 |
BSE filing, NSE: WOCKPHARMA. Summary written from the filing by ALFA Finder's alert engine.
Wockhardt Ltd: key numbers
- Share price
- ₹1,901.10
- Market cap
- ₹30,895 Cr
- Revenue (annual)
- ₹3,373 Cr
- Net profit (annual)
- ₹213.0 Cr
- P/E (TTM)
- 75.5×Sector 48.7×
- Promoter holding
- 49.32%+0.24% QoQ
- FII holding
- 7.02%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Wockhardt Ltd
All →Wockhardt Employee Stock Options
Wockhardt allotted 20,000 equity shares at Rs.5 exercise price under its ESOS 2011 scheme. Paid-up capital increases to 16,25,12,169 shares of Rs.5 each.
Wockhardt Board Meeting Date
Wockhardt Ltd intimated that its Board will meet on 2 Nov 2026 to approve Q1 FY27 unaudited results. The trading window remains closed until 48 hours post-declaration.
Wockhardt Other Announcement
The company submitted its quarterly shareholding pattern for the period ended September 30, 2026, in compliance with SEBI Regulation 31.
Wockhardt Legal & Regulatory
Wockhardt Limited received an order from the Commissioner of Customs imposing a ₹5 Crore penalty and ₹10 Crore redemption fine. The company plans to challenge this order.
- Value
- ₹15.00 Cr
Wockhardt Legal & Regulatory
Wockhardt Limited received an adjudication order from the Commissioner of Customs imposing penalties and redemption fines aggregating to ₹16 Crore regarding API mis-classification.
- Value
- ₹16.00 Cr
Wockhardt Other Announcement
Wockhardt Limited submitted the Monitoring Agency Report for the quarter ended June 30, 2026. The report confirms no deviation in the utilization of QIP proceeds.
Other fund raise announcements
All →Sudarshan Pharma Industries Fund Raise of ₹72 Cr
Sudarshan Pharma's board approved up to Rs. 72 Crore of preferential convertible warrants for promoters Hemal and Sachin Mehta. Shareholder approval will be sought at an EGM.
- Value
- ₹72.00 Cr
Flywings Simulator Training Centre Fund Raise of ₹68.2 Cr
Flywings Simulator's board approved Rs. 68.20 Crore fully convertible warrants on a preferential basis. Promoter Rupal Mandavia is allotted Rs. 25 Crore, subject to shareholder approval.
- Value
- ₹68.20 Cr
Kanel Industries Fund Raise of ₹16.99 Cr
Kanel Industries' board approved a rights issue of 42.52 lakh equity shares at Rs.39.95 each. The issue aggregates about Rs.16.99 Crore, with record date 13 November 2026.
- Value
- ₹16.99 Cr
- Execution
- Rights issue opens 23 November 2026 and closes 30 November 2026
Sudarshan Pharma Industries Fund Raise
Board approved issuing up to 72 Crore warrants to promoters on a preferential basis. Pricing per Reg 164 is pending, with no fixed rupee value stated.
GAIL (India) Fund Raise
GAIL Board approved in principle the IPO of subsidiary GAIL Gas Limited on Indian exchanges. GAIL will dilute its GGL equity up to 25%.
Gujarat Inject (Kerala) Fund Raise of ₹3 Cr
Gujarat Inject Kerala's board approved a Rs.3 Crore preferential warrant issue to public investors. Authorised capital will rise to Rs.17.63 Crore, subject to shareholder approval.
- Value
- ₹3.00 Cr